Goitre – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Goitre Market Outlook

Thelansis’s “Goitre Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Goitre treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Goitre Overview

Goiter, an enlargement of the thyroid gland, can arise from various causes. The primary cause, accounting for over 90% worldwide, is iodine deficiency in the diet, resulting in a simple goiter. Numerous pathogenic mechanisms underlie goiter formation. One prominent factor is iodine deficiency, particularly in regions lacking public health interventions to counter it, termed endemic goiter. Additionally, inflammatory thyroid gland disorders such as autoimmune thyroiditis, postpartum thyroiditis, silent thyroiditis, radiation thyroiditis, subacute thyroiditis, and suppurative thyroiditis can induce thyroid enlargement, leading to goiter. In these cases, the term "goiter" isn't used to characterize the disorder, as the enlargement stems from the inflammatory process and subsides once inflammation resolves. Instead, goiter becomes one among several symptoms of inflammatory thyroid disorders. Conditions like Grave's disease, toxic nodular goiter, and toxic multinodular goiter, causing hyperthyroidism, can also lead to goiter formation. This goiter can encompass single or multiple nodules and is known as nodular goiter or nontoxic multinodular goiter, often associated with normal thyroid function. Other triggers encompass thyroid cancer, granulomatous disorders, and infiltrative thyroid diseases. Thyroid enlargement or goiter emerges as an adaptive reaction of thyroid follicular cells to disruptions in thyroid hormone production. The predominant cause remains iodine deficiency, although Hashimoto's thyroiditis becomes significant in iodized salt-consuming countries or those without iodine deficiency issues. Nevertheless, iodine deficiency remains the prevalent global cause. Goiters exhibit diverse morphological, hormonal, and clinical manifestations, and not all are linked to iodine deficiency, with genetic, demographic, and environmental factors contributing. Simple goiter generally carries a favorable prognosis. However, substantial enlargement may lead to compression of adjacent structures, resulting in breathing difficulties, swallowing challenges, and hoarseness. It's vital to distinguish between benign and malignant thyroid enlargement causes. Surgical intervention becomes an option if the goiter continues to grow. The prognosis for goiter associated with conditions like Grave's disease or Hashimoto's thyroiditis hinges on the underlying cause of thyroid enlargement. Consequences of goiter encompass hypothyroidism, hyperthyroidism, further enlargement, retrosternal extension, nodule formation, and thyroid cancer detection. These manifestations constitute goiter-associated presentations or clinical entities and are not classified as complications. Potential complications of simple goiter include tracheal compression with tracheomalacia, the Iodo-Basedow phenomenon (inducing hyperthyroidism upon iodine exposure), and intra-nodular hemorrhage or necrosis. Benign goiters can be managed with thyroid hormone therapy. Levothyroxine sodium, taken once daily, is the most widely employed thyroid hormone. Liothyronine sodium requires more frequent dosing. Desiccated thyroid powder, thyroglobulin, and liotrix yield less predictable results upon ingestion.

• Estimates suggest that goiters affect around 200 million individuals among the 800 million with iodine-deficient diets.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: